Pregnancies among high-risk women in the first ever HIV vaccine efficacy trial [7]

AIDS

Volumn 17, Issue 5, 2003, Pages 787-788

  Brown Peterside, Pamela ^a   Ren, Leigh ^a   Hirsch, Adrian ^b   Drucker, Marc ^b   Koblin, Beryl A ^a  

^a NEW YORK BLOOD CENTER   (United States)

^b VaxGen Inc   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; HUMAN IMMUNODEFICIENCY VIRUS VACCINE;

ADULT; CLINICAL TRIAL; DRUG EFFICACY; DRUG SAFETY; FEMALE; HIGH RISK POPULATION; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INCIDENCE; LETTER; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; SEXUAL TRANSMISSION;

ADOLESCENT; ADULT; AIDS VACCINES; CLINICAL TRIALS; FEMALE; HIV INFECTIONS; HUMANS; MIDDLE AGED; PATIENT SELECTION; PREGNANCY;

EID: 0037471341     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-200303280-00031     Document Type: Letter

References (5)

1. Bennett JC. Inclusion of women in clinical trials - policies for population subgroups. N Engl J Med 1993; 329:288-292.
2. Keefer MC, Wolff M, Gorse GJ, Graham BS, Corey L, Clements-Mann ML, et al., and the NIAID AIDS Vaccine Evaluation Group. Safety profile of phase I and II preventive HIV type 1 envelope vaccination: experience of the NIAID AIDS Vaccine Evaluation Group. AIDS Res Human Retroviruses 1997; 13:1163-1177.
3. Harro C, Judson FN, Brown SJ, Marmor M, Li E, Alonzo G, et al. Successful recruitment and conduct of the first HIV vaccine efficacy trial in North America and Europe. In: International AIDS Conference. 9-14 July 2000, Durban, South Africa. [Abstract WeOrC580].
4. Fee LM, Fleming PL. Trends in human immunodeficiency virus diagnoses among women in the United States, 1994-1998. J Am Women Med Assoc 2001; 56:94-99.
5. Seage GE III, Metzger D, Holte S, Buchbinder S, Koblin B, Celum C. Are US populations appropriate for trials of human immunodeficiency virus vaccine? The HIVNET Vaccine Preparedness Study. Am J Epidemiol 2001; 153:619-627.